GSK and Sanofi ready to start human trials on COVID-19 potential vaccine

By: Miguel A. Rodriguez

09:45, 14 September 2020

The relevant result to be available by the end of the year

The middle of the week came with good news from GlaxoSmithKline and Sanofi. The largest vaccine maker globally and the French drugmaker announced that their potential COVID-19 #vaccine would undergo human testing.

It all started in April when the two companies joined forces to develop a protein-based #COVID-19 vaccine, which so far showed promising results in clinical trials. According to them, the human clinical trial is designed to assess the vaccine's safety, tolerability, and immune response. If all goes well, the first results will be available by December. The clinical trial will occur at eleven sites across the US, and more than 400 people will take part. 

Combined, GSK and Sanofi have the largest developing and manufacturing capability in the world, and their target is to produce 1 billion doses of vaccine in 2021.

To speed up the vaccine's development and to secure 100 million doses, the US government gave the companies $2.1 billion.  Also, the UK is said to receive up to 60 million doses of vaccine if proven effective by undergoing trials.

The market reacted positively to the news, and GSK stock price gained more than 2%, while Sanofi added over 1%. 

While you are here, don't forget to check-out our Corona Blend!

Sources: theguardian.com, finance.yahoo.com

Share this article

This information/research prepared by Miguel A. Rodriguez does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. The research analyst primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views and consequently any person acting on it does so entirely at their own risk.The research provided does not constitute the views of KW Investments Ltd nor is it an invitation to invest with KW Investments Ltd. The research analyst also certifies that no part of his/her compensation was, is, or will be, directly, or indirectly, related to specific recommendations or views expressed in this report.The research analyst in not employed by KW Investments Ltd. You are encouraged to seek advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit that conforms to your specific investment objectives, financial situation, or particular financial needs before making a commitment to invest. The laws of the Republic of Seychelles shall govern any claim relating to or arising from the contents of the information/ research provided.